User profiles for Amélie Lusque
 | Amélie LUSQUEBiostatistician, Institut Claudius Regaud Verified email at iuct-oncopole.fr Cited by 3288 |
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
M Delaunay, J Cadranel, A Lusque… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
N Guibert, M Delaunay, A Lusque, N Boubekeur… - Lung Cancer, 2018 - Elsevier
Background Inhibitors of the PD-1/PD-L1 immune checkpoint have become a standard of
care in non-small cell lung cancer (NSCLC). Patient selection, currently based on PD-L1 …
care in non-small cell lung cancer (NSCLC). Patient selection, currently based on PD-L1 …
Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis …
V Diéras, E Deluche, A Lusque, B Pistilli, T Bachelot… - Cancer Research, 2022 - AACR
Background: The HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd)
demonstrated efficacy in heavily pretreated HER2-over- and HER2-low expressing …
demonstrated efficacy in heavily pretreated HER2-over- and HER2-low expressing …
Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial
…, P Olivier, M Ayyoub, M Mounier, A Lusque… - Clinical Cancer …, 2021 - AACR
Purpose: TNF blockers can be used to manage gastrointestinal inflammatory side effects
following nivolumab and/or ipilimumab treatment in patients with advanced melanoma. Our …
following nivolumab and/or ipilimumab treatment in patients with advanced melanoma. Our …
[HTML][HTML] Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2
remains the cornerstone to define the therapeutic strategy for breast cancer patients. We …
remains the cornerstone to define the therapeutic strategy for breast cancer patients. We …
Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey
…, MP Chenard, B Cabarrou, A Lusque… - Blood, The Journal …, 2022 - ashpublications.org
According to expert guidelines, lymph node surgical excision is the standard of care for
lymphoma diagnosis. However, core needle biopsy (CNB) has become widely accepted as part …
lymphoma diagnosis. However, core needle biopsy (CNB) has become widely accepted as part …
Comparison of management and outcomes in ERBB2-low vs ERBB2-zero metastatic breast cancer in France
O de Calbiac, A Lusque, A Mailliez… - JAMA network …, 2022 - jamanetwork.com
Importance ERBB2-low (ie,ERBB2immunohistochemistry score of 1+ or 2+ in the absence
ofERBB2gene amplification) breast cancer (BC) is a new entity, with emerging dedicated …
ofERBB2gene amplification) breast cancer (BC) is a new entity, with emerging dedicated …
Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched …
E Pons-Tostivint, Y Kirova, A Lusque… - Annals of Surgical …, 2019 - Springer
Introduction Improvement in overall survival (OS) by locoregional treatment (LRT) of the
primary tumor in de novo metastatic breast cancer (MBC) patients remains controversial. …
primary tumor in de novo metastatic breast cancer (MBC) patients remains controversial. …
The STEMRI trial: Magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma stem-like cells
Despite maximally safe resection of the magnetic resonance imaging (MRI)–defined contrast-enhanced
(CE) central tumor area and chemoradiotherapy, most patients with …
(CE) central tumor area and chemoradiotherapy, most patients with …
Body mass index as a major risk factor for severe breast cancer-related lymphedema
H Leray, J Malloizel-Delaunay, A Lusque… - Lymphatic Research …, 2020 - liebertpub.com
Background: A few studies have examined the characteristics of severe breast cancer-related
lymphedema (BCRL). This study aims at analyzing the factors associated with severe …
lymphedema (BCRL). This study aims at analyzing the factors associated with severe …